Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Update

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the target of a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 1,859,100 shares, a growth of 37.0% from the May 30th total of 1,356,600 shares. Approximately 5.7% of the shares of the stock are sold short. Based on an average trading volume of 445,300 shares, the days-to-cover ratio is presently 4.2 days.

Several hedge funds and other institutional investors have recently bought and sold shares of HBIO. BNP Paribas Arbitrage SA grew its stake in shares of Harvard Bioscience by 635.4% during the first quarter. BNP Paribas Arbitrage SA now owns 7,567 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 6,538 shares during the last quarter. Mackay Shields LLC grew its stake in shares of Harvard Bioscience by 57.5% during the fourth quarter. Mackay Shields LLC now owns 38,440 shares of the medical instruments supplier’s stock worth $123,000 after buying an additional 14,040 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Harvard Bioscience by 47.9% during the fourth quarter. Rhumbline Advisers now owns 48,908 shares of the medical instruments supplier’s stock worth $156,000 after buying an additional 15,839 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Harvard Bioscience by 7.6% during the fourth quarter. Bank of America Corp DE now owns 82,642 shares of the medical instruments supplier’s stock worth $262,000 after buying an additional 5,835 shares during the last quarter. Finally, Squarepoint Ops LLC grew its stake in shares of Harvard Bioscience by 74.0% during the fourth quarter. Squarepoint Ops LLC now owns 97,592 shares of the medical instruments supplier’s stock worth $310,000 after buying an additional 41,495 shares during the last quarter. 74.71% of the stock is currently owned by hedge funds and other institutional investors.

HBIO has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. Janney Montgomery Scott cut shares of Harvard Bioscience from a “buy” rating to a “neutral” rating and set a $2.00 price objective on the stock. in a research note on Monday, July 8th. Finally, ValuEngine raised shares of Zogenix from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 27th.



Shares of NASDAQ HBIO traded up $0.02 during midday trading on Friday, reaching $1.87. 280,475 shares of the company were exchanged, compared to its average volume of 858,651. The company’s 50-day moving average price is $2.05. The stock has a market capitalization of $70.48 million, a PE ratio of 12.47 and a beta of 1.48. Harvard Bioscience has a one year low of $1.51 and a one year high of $6.70. The company has a current ratio of 2.22, a quick ratio of 1.12 and a debt-to-equity ratio of 0.79.

Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.01. The firm had revenue of $28.23 million for the quarter, compared to analysts’ expectations of $28.50 million. Harvard Bioscience had a negative net margin of 1.45% and a positive return on equity of 5.95%. Analysts forecast that Harvard Bioscience will post 0.09 EPS for the current fiscal year.

About Harvard Bioscience

Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.

Featured Story: What are momentum indicators and what do they show?

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.